Azathioprine showed no clear difference in relapse at 18 months compared with cyclophosphamide (moderate certainty).
Azathioprine showed no clear difference in serious adverse events compared with cyclophosphamide (moderate certainty).
Azathioprine showed no clear difference in infections compared with cyclophosphamide (moderate certainty).
It is very uncertain whether calcineurin inhibitor changes treatment response at 3 to 6 months: partial remission compared with IV cyclophosphamide (very low certainty).
Calcineurin inhibitor probably leads to lower adverse events: treatment failure at 6 months (non response, serious… compared with IV cyclophosphamide (moderate certainty).
Calcineurin inhibitor probably leads to lower adverse events: medications ceased due to adverse events compared with IV cyclophosphamide (moderate certainty).
Calcineurin inhibitor showed no clear difference in adverse events: serious infections compared with IV cyclophosphamide (moderate certainty).
Calcineurin inhibitor showed no clear difference in adverse events: death compared with IV cyclophosphamide (low certainty).
IV showed no clear difference in complete remission compared with oral cyclophosphamide (low certainty).
IV showed no clear difference in partial remission compared with oral cyclophosphamide (low certainty).
IV showed no clear difference in continuing remission at one year compared with oral cyclophosphamide (low certainty).
IV showed no clear difference in adverse events: renal insufficiency compared with oral cyclophosphamide (low certainty).
It is very uncertain whether IV changes adverse events: bacterial infection compared with oral cyclophosphamide (very low certainty).
It is very uncertain whether IV changes adverse events: vomiting compared with oral cyclophosphamide (very low certainty).
IV showed no clear difference in adverse events: alopecia compared with oral cyclophosphamide (low certainty).
Calcineurin inhibitor may leads to higher treatment response at 3 to 6 months: complete or partial remission compared with IV cyclophosphamide (low certainty).
Calcineurin inhibitor may leads to higher treatment response at 3 to 6 months: complete remission compared with IV cyclophosphamide (low certainty).
It is very uncertain whether mycophenolate mofetil (MMF) changes death compared with IV cyclophosphamide (CPA) (very low certainty).
Mycophenolate mofetil (MMF) + tacrolimus (TAC) showed no clear difference in partial renal remission compared with IV cyclophosphamide (CPA) (low certainty).
Mycophenolate mofetil (MMF) + tacrolimus (TAC) may leads to higher stable kidney function compared with IV cyclophosphamide (CPA) (low certainty).